Beyond The Numbers: 4 Analysts Discuss 4D Molecular Therapeutics Stock

4 analysts have shared their evaluations of 4D Molecular Therapeutics (NASDAQ:FDMT) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings31000Last 30D010001M Ago000002M Ago000003M Ago30000Analysts have recently evaluated 4D Molecular Therapeutics and provided 12-month price targets. The average target is $28.5, accompanied by a high estimate of $38.00 and a low estimate of $25.00. A decline of 5.0% from the prior average price target is evident in the current average.Deciphering Analyst Ratings: An In-Depth AnalysisIn examining recent analyst actions, we gain insights into how financial experts perceive 4D Molecular Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.AnalystAnalyst FirmAction TakenRatingCurrent Price TargetPrior Price TargetLisa WalterRBC CapitalMaintainsOutperform$26.00$26.00Salveen RichterRoth CapitalLowersBuy$38.00$44.00Geulah LivshitsChardan CapitalMaintainsBuy$25.00$25.00Geulah LivshitsChardan CapitalMaintainsBuy$25.00$25.00Key Insights:Action Taken:Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 4D Molecular Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.Rating:Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.Price Targets:Analysts predict movements in price targets, offering estimates for 4D Molecular Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.Capture valuable insights into 4D Molecular Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.Stay up to date on 4D Molecular Therapeutics analyst ratings.If you are interested in following small-cap stock news and performanceyou can start by tracking it here.Delving into 4D Molecular Therapeutics's Background4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.4D Molecular Therapeutics: Delving into FinancialsMarket Capitalization Analysis:Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.Positive Revenue Trend:Examining 4D Molecular Therapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of200.0%as of 30 June, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.Net Margin:4D Molecular Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of-364386.67%,the company may face hurdles in effective cost management.Return on Equity (ROE):4D Molecular Therapeutics's ROE excels beyond industry benchmarks, reaching-12.27%. This signifies robust financial management and efficient use of shareholder equity capital.Return on Assets (ROA):The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of-11.05%,the company may need to address challenges in generating satisfactory returns from its assets.Debt Management:With a below-average debt-to-equity ratio of0.05, 4D Molecular Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.The Significance of Analyst Ratings ExplainedExperts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores inBenzinga Pro.Which Stocks Are Analysts Recommending Now?Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more.Click here to stay ahead of the market.This article was generated by Benzinga's automated content engine and reviewed by an editor.FDMT4D Molecular Therapeutics Inc$11.15-1.06%OverviewMarket News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. . .Add Comment|1Posted In:Analyst RatingsBZI-AAR